Balancing Creativity with Compliance: Meet Kirsten Searle, Manager of Pharma Development
Discover how Kirsten Searle is enhancing project management excellence at Nanopharm. Hear about her philosophy on balancing pragmatic process with scientific innovation in a fast-paced CRO environment.
Inhaled Generic Bioequivalence Modeling Approaches
Learn how advanced in vitro and in silico modeling help generics companies overcome complex bioequivalence hurdles for orally inhaled drug products (OIDPs).
First Reflections on RDD 2026: FDA Guidance Updates Highlight Progress for NGP pMDIs
Discover first reflections on RDD 2026 from Phoenix, Arizona, highlighting the impact of the research programme funded by FDA and exemplifying Nanopharm’s recognized scientific contributions to supporting the transition to next-generation propellant metered dose inhalers (pMDIs).
From ‘Quality Police’ to Lighthouse Leadership: Transforming QA in Pharma | Nanopharm
Discover how Nanopharm is redefining Quality Assurance as a strategic enabler in drug development. Learn how risk-based QA, innovation, and digital tools are improving outcomes for inhaled and nasal therapies.
Nanopharm Newsletter November 2024
Nanopharm is leading innovation in OINDP, inhalation, and nasal drug delivery with FDA collaboration and advanced spray-drying technology.
Nanopharm & FLUIDDA Interviews on SmartTrack: In Vitro-In Silico Approaches for Demonstrating Bioequivalence for OINDP
To support generic drug companies in obtaining a market license for their orally inhaled drug products (OIDPs), Nanopharm and FLUIDDA entered into an exclusive collaboration to combine Nanopharm’s SmartTrack™ with FLUIDDA’s Functional Respiratory Imaging technology to create a unique in-vitro in-silico platform. This allows pharma companies to shorten their clinical pathways – and potentially avoid […]
A Holistic Demonstration of SmartTrack™ and New Ways of Collaborating Combine for a Successful FDA Workshop
Nasal spray innovation with micellar delivery of Cyclosporine A holds promise in combating SARS-CoV-2 infections
Optimising batch selection to increase success of PK studies for bioequivalence
Uncover Nanopharm’s SmartTrack approach for successful Pharmacokinetic and Bioequivalence studies in OINDP, using PBPK modelling.
Alternative Regulatory Pathway for Generic Inhaled Drugs
Uncover the pathways for generic OINDP and the challenges and solutions in the pharmaceutical regulatory landscape for inhalation drug products.
Physiologically-based Pharmacokinetic Models (PBPK) for OINDPs
Aptar Pharma discusses Physiologically based PK models for OINDPs.